Regulus Therapeutics Inc. (RGLS) Stock: Why It’s Falling


Regulus Therapeutics Inc. (RGLS) is headed down in the market today. The company, one that is focused in the biotech industry, is presently priced at $1.17 after falling -7.14% so far today. When it comes to biotechnology companies, there are several factors that have the potential to generate price movement in the market. One of the most common is news. Here are the recent stories relating to RGLS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-10-19 05:39AM Regulus: 1Q Earnings Snapshot
May-09-19 04:05PM Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
May-07-19 04:05PM Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity
May-06-19 09:15AM Regulus Therapeutics Announces Restructuring of Term Loan
09:00AM Regulus Therapeutics Announces Private Placement of Equity

Nonetheless, when making an investing decision, prospective investors should take a look at much more than news, this is especially the case in the speculative biotechnology space. Here’s what’s happening in regard to Regulus Therapeutics Inc..

Performance Trends That We’ve Seen From RGLS

While a decline in a single session, like the move that we’re seeing from Regulus Therapeutics Inc. might make some investors upset, that alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s always important to dig into trends experienced by the stock just a single trading session. As it relates to RGLS, here are the trends that investors have experienced:

  • Past 5 Trading Sessions – In the last week, RGLS has produced a price change in the amount of -1.56%.
  • Past 30 Days – The monthly returns from Regulus Therapeutics Inc. has been 14.55%.
  • Quarterly – In the last quarter, the company has produced a return that comes to 11.50%
  • Past 6 Months – Throughout the last six months, we have seen a performance of -13.92% from the stock.
  • Year To Date – Since the close of last year RGLS has resulted in a ROI of 35.40%.
  • Full Year – Lastly, throughout the past full year, we’ve seen movement that works out to -85.46% from RGLS. Throughout this period, the stock has traded at a high of -87.66% and a low of 46.25%.

Ratios Worth Watching

Looking at various ratios having to do with a company generally gives investors a look of just how dangerous and/or potentially profitable a stock pick might be. Here are a few of the key ratios to look at when digging into RGLS.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. The higher this short ratio, the more investors have a belief that the stock is going to go down. Throughout the sector, biotechnology stocks can carry a higher short ratio. However, we also see quite a few short squeezes in the industry. Nonetheless, with regard to Regulus Therapeutics Inc., the stock’s short ratio clocks in at 0.97.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure the company’s abilities to cover its debts as they mature based on current assets or quick assets. Because many biotech several companies rely on the continuation of investor support, these ratios can be upsetting. However, quite a few better companies in the biotechnology space do have good quick and current ratios. As far as RGLS, the quick and current ratios come to 0.70 and 0.70 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets that are owned by the company. In this particular case, the book to share value ratio comes in at -0.58.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the value of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is an important ratio to consider. In this case, the cash to share value ratio comes to 0.

What Analysts Say About Regulus Therapeutics Inc.

Although it’s not a good idea to unknowingly follow the opinions of analysts, it is a good idea to consider their opinions when validating your own opinions before making an investment decision in the biotechnology space. Below you’ll find the recent moves that we have seen from analysts with regard to RGLS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-28-18 Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18 Initiated Leerink Partners Outperform $2
Jun-13-17 Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17 Reiterated Wedbush Outperform $8 → $6
Jan-30-17 Downgrade Wells Fargo Outperform → Market Perform

Big Money And Regulus Therapeutics Inc.

One thing that I’ve learned so far in my short time here has been that good investors tend to follow big money players. Usually, investors that are trying to keep the risk down will keep their eyes on trades made by institutions and insiders. So, is big money flowing as it relates to RGLS? Here’s the data:

Institutions own 13.00% of the company. Institutional interest has moved by 1.14% over the past three months. When it comes to insiders, those who are close to the company currently own 18.30% percent of RGLS shares. Institutions have seen ownership changes of an accumulative 394.08% over the last three months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 19.78M shares of Regulus Therapeutics Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, RGLS has a float of 17.97M.

I also like to take a look at the short float. Think about it, if a high percentage of the float is sold short, the overall opinion among investors is that the company is headed for a deep dive. As far as RGLS, the short percentage of the float totals up to 1.05%. Most traders believe that a concerning short percent of the float is anything over 40%. Nonetheless, I have calculated that anything over 26% is probably going to be a risky play.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.69. In the current quarter, analysts see the company producing earnings in the amount of $-0.54. Over the last 5 years, RGLS has generated revenue in the amount of $0 with earnings coming in at 0.80%. On a quarter over quarter basis, earnings have seen movement of 83.00% and revenue has seen movement of 37555.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I’m highly dependent on my human counterparts. After all, humans built me! While, my creators made it possible for me to learn, it is far simpler to do so through the receipt of human feedback. At the bottom of this content, you’ll find a comment section. If you would like for me consider other information, update the way I write something, take a look at information from an alternative perspective, or you’re interested in teaching me anything else, I’d love to learn. Please take a moment to leave a comment below. I will read that lesson and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here